Last reviewed · How we verify

Rescue Medication: Loratadine tablets — Competitive Intelligence Brief

Rescue Medication: Loratadine tablets (Rescue Medication: Loratadine tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: H1-receptor antagonist (second-generation/non-sedating antihistamine). Area: Allergy/Immunology.

phase 3 H1-receptor antagonist (second-generation/non-sedating antihistamine) H1 histamine receptor Allergy/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Rescue Medication: Loratadine tablets (Rescue Medication: Loratadine tablets) — ALK-Abelló A/S. Loratadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without significant central nervous system penetration.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Rescue Medication: Loratadine tablets TARGET Rescue Medication: Loratadine tablets ALK-Abelló A/S phase 3 H1-receptor antagonist (second-generation/non-sedating antihistamine) H1 histamine receptor
fluticasone furoate, fexofenadine fluticasone furoate, fexofenadine GlaxoSmithKline marketed Corticosteroid/antihistamine combination Glucocorticoid receptor (fluticasone furoate); H1 histamine receptor (fexofenadine)
adrenaline, promethazine, hydrocortisone adrenaline, promethazine, hydrocortisone University of Kelaniya marketed Combination therapy: sympathomimetic, antihistamine, corticosteroid Adrenergic receptors (α1, α2, β1, β2); H1 histamine receptor; glucocorticoid receptor
Morphine-Promethazine Morphine-Promethazine Tel-Aviv Sourasky Medical Center marketed Opioid analgesic combination Mu-opioid receptor (morphine); H1 histamine receptor (promethazine)
olopatadine (OLO) olopatadine (OLO) University of Chicago marketed Selective H1-receptor antagonist / mast cell stabilizer H1 histamine receptor
Azelastine - intranasal application Azelastine - intranasal application Association Asthma, Bulgaria marketed Selective H1-receptor antagonist (intranasal antihistamine) H1 histamine receptor
Diphenhydramine 5% Diphenhydramine 5% Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology marketed H1 receptor antagonist (first-generation antihistamine) H1 histamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (H1-receptor antagonist (second-generation/non-sedating antihistamine) class)

  1. ALK-Abelló A/S · 1 drug in this class
  2. Hoffmann-La Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rescue Medication: Loratadine tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/rescue-medication-loratadine-tablets. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: